Tag - VXRT

Developments

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Vaxart (NASDAQ:VXRT) reported positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Norovirus is the leading cause of acute viral gastroenteritis in...

July 7, 2023

Markets

Brookline starts Vaxart at buy; PT $6

Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...

August 15, 2019

Tag - VXRT

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Brookline starts Vaxart at buy; PT $6

General

More